The Dutch Competition Authority publishes a sector report on the impact of biosimilars on competition between TNF-alfa inhibitors

Dutch competition authority ACM publishes a sector report on the impact of biosimilars on competition between TNF-alfa inhibitors* The Dutch competition authority, ACM, initiated a market study in 2018 into the effect of the introduction of biosimilars on the competition between TNF alfa inhibitors. TNF-alfa inhibitors are biological medicines that are mainly used by rheumatoid arthritis patients, but also by patients with other autoimmune diseases. The ACM decided to conduct a sector study into this group of medicines because TNF-alfa inhibitors are an important medicines group with a high turnover, high numbers of patients and persistently high prices, while there are relatively many therapeutic alternatives available. By investigating the functioning of the market in this segment,

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Authors

Quotation

Mariska Van De Sanden, Janneke Kohlen, Pauline Kuipers, The Dutch Competition Authority publishes a sector report on the impact of biosimilars on competition between TNF-alfa inhibitors, 30 September 2019, e-Competitions Bulletin October 2019, Art. N° 91903

Visites 172

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues